Yang S, Seo J, Choi J, Kim S, Kuk Y, Park K
Mol Cancer. 2025; 24(1):47.
PMID: 39953555
PMC: 11829473.
DOI: 10.1186/s12943-025-02250-9.
He X, Deng B, Zhang C, Zhang G, Yang F, Zhu D
Mol Med. 2025; 31(1):53.
PMID: 39924492
PMC: 11809008.
DOI: 10.1186/s10020-025-01086-9.
Lyukmanova E, Kirichenko A, Medyanik I, Yashin K, Kirpichnikov M, Bychkov M
Biomedicines. 2025; 12(12.
PMID: 39767739
PMC: 11673896.
DOI: 10.3390/biomedicines12122834.
Martinez M, Nan K, Bao Z, Bacchetti R, Yuan S, Tyler J
PLoS Biol. 2024; 22(12):e3002930.
PMID: 39666682
PMC: 11637276.
DOI: 10.1371/journal.pbio.3002930.
Yun W, Zhang J, Ji M
J Mol Histol. 2024; 55(6):1307-1314.
PMID: 39316256
DOI: 10.1007/s10735-024-10271-9.
Injectable Hydrogel-Encapsulating Pickering Emulsion for Overcoming Lenvatinib-Resistant Hepatocellular Carcinoma via Cuproptosis Induction and Stemness Inhibition.
Li X, Tang C, Ye H, Fang C
Polymers (Basel). 2024; 16(17).
PMID: 39274051
PMC: 11397159.
DOI: 10.3390/polym16172418.
Mitochondrial Deoxyguanosine Kinase Induces 5-Fluorouracil Chemotherapy Sensitivity through Autophagy.
Dong L, Liu S, Sun W, Liu S, Zhang N, Zhang S
Curr Cancer Drug Targets. 2024; 25(3):306-316.
PMID: 39171468
DOI: 10.2174/0115680096337375240801080008.
The advent of a pan-collagenous CLOVIS POINT for pathotropic targeting and cancer gene therapy, a retrospective.
Gordon E, Hall F
Front Mol Med. 2024; 3:1125928.
PMID: 39086682
PMC: 11285703.
DOI: 10.3389/fmmed.2023.1125928.
Atractylenolide II combined with Interferon-γ synergistically ameliorates colorectal cancer progression and by blocking the NF-kB p65/PD-L1 pathway.
Wu Y, Dai S, Zhang Y, Li Z, Zhu B, Liu Q
J Cancer. 2024; 15(13):4328-4344.
PMID: 38947390
PMC: 11212082.
DOI: 10.7150/jca.96647.
Identification of placenta-specific protein 1 (PLAC-1) expression on human PC-3 cell line-derived prostate cancer stem cells compared to the tumor parental cells.
Farhangnia P, Ghods R, Falak R, Zarnani A, Delbandi A
Discov Oncol. 2024; 15(1):251.
PMID: 38943028
PMC: 11213845.
DOI: 10.1007/s12672-024-01121-x.
Bone Marrow Mesenchymal Stem Cells Promote Ovarian Cancer Cell Proliferation via Cytokine Interactions.
Wang K, Chang Y, Ding D
Int J Mol Sci. 2024; 25(12).
PMID: 38928452
PMC: 11203416.
DOI: 10.3390/ijms25126746.
Deguelin Restores Paclitaxel Sensitivity in Paclitaxel-Resistant Ovarian Cancer Cells via Inhibition of the EGFR Signaling Pathway.
Bae S, Bae S, Kim H, Lim Y, Kim G, Park I
Cancer Manag Res. 2024; 16:507-525.
PMID: 38827785
PMC: 11144006.
DOI: 10.2147/CMAR.S457221.
The Invasion Factor ODZ1 Is Upregulated through an Epidermal Growth Factor Receptor-Induced Pathway in Primary Glioblastoma Cells.
Velasquez C, Gutierrez O, Carcelen M, Fernandez-Luna J
Cells. 2024; 13(9.
PMID: 38727302
PMC: 11083495.
DOI: 10.3390/cells13090766.
Pharmacological p38 MAPK inhibitor SB203580 enhances AML stem cell line KG1a chemosensitivity to daunorubicin by promoting late apoptosis, cell growth arrest in S-phase, and miR-328-3p upregulation.
Bahattab S, Assiri A, Alhaidan Y, Trivilegio T, AlRoshody R, Huwaizi S
Saudi Pharm J. 2024; 32(6):102055.
PMID: 38699598
PMC: 11063648.
DOI: 10.1016/j.jsps.2024.102055.
Developing a pragmatic consensus procedure supporting the ICH S1B(R1) weight of evidence carcinogenicity assessment.
Bassan A, Steigerwalt R, Keller D, Beilke L, Bradley P, Bringezu F
Front Toxicol. 2024; 6:1370045.
PMID: 38646442
PMC: 11027748.
DOI: 10.3389/ftox.2024.1370045.
In silico identification and in vitro validation of alpha-hederin as a potent inhibitor of Wnt/β-catenin signaling pathway in breast cancer stem cells.
Saliu T, Seneviratne N, Faizan M, Rajagopalan U, Perera D, Adhikari A
In Silico Pharmacol. 2024; 12(1):31.
PMID: 38617708
PMC: 11014832.
DOI: 10.1007/s40203-024-00199-z.
Pirfenidone ameliorates alcohol-induced promotion of breast cancer in mice.
Li H, Xu M, Chen D, Wen W, Luo J
Front Oncol. 2024; 14:1351839.
PMID: 38590657
PMC: 10999600.
DOI: 10.3389/fonc.2024.1351839.
Revealing role of epigenetic modifiers and DNA oxidation in cell-autonomous regulation of Cancer stem cells.
Ferrer-Diaz A, Sinha G, Petryna A, Gonzalez-Bermejo R, Kenfack Y, Adetayo O
Cell Commun Signal. 2024; 22(1):119.
PMID: 38347590
PMC: 10863086.
DOI: 10.1186/s12964-024-01512-1.
p38 Molecular Targeting for Next-Generation Multiple Myeloma Therapy.
Morales-Martinez M, Vega M
Cancers (Basel). 2024; 16(2).
PMID: 38254747
PMC: 10813990.
DOI: 10.3390/cancers16020256.
Recruitment of BAG2 to DNAJ-PKAc scaffolds promotes cell survival and resistance to drug-induced apoptosis in fibrolamellar carcinoma.
Lauer S, Omar M, Golkowski M, Kenerson H, Lee K, Pascual B
Cell Rep. 2024; 43(2):113678.
PMID: 38236773
PMC: 10964278.
DOI: 10.1016/j.celrep.2024.113678.